Cory Renauer
Value, research analyst, biotech, small-cap

NPS Pharmaceuticals Has A Billion Plus Blockbuster On Its Hands

NPS Pharmaceuticals (NASDAQ:NPSP) has an orphan blockbuster on its hands. The company is giddy with excitement over the successful launch of its recently approved therapy. Priced at $295,000 per year, teduglutide, marketed in the US as Gattex and internationally as Revestive, raised a great deal of skepticism earlier this year. I'm going to take a closer look at the US launch of Gattex and show you why I believe NPS will pass $2 billion in annual teduglutide sales within the next five years.

The costs of short bowel syndrome

Short bowel syndrome is an extremely debilitating condition that prior to the launch of teduglutide was largely untreatable. The condition typically results from the surgical resection of the intestine...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details